Cancer medicine journal最新文献

{"title":"Discordant ERBB2 Status and Genome Wide DNA Copy Number Alterations in Breast Cancer and Synchronous Lymph Node Metastasis: A Case Report and Literature Review.","authors":"Ruchi Singhal,&nbsp;Alexander Yu,&nbsp;Song Han,&nbsp;Hai Wu,&nbsp;Guangyu Li,&nbsp;Jing He,&nbsp;Jianli Dong","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Erb-b2 receptor tyrosine kinase 2 (ERBB2) is a biomarker in the management of breast cancer (BC). Changes of ERBB2 status in primary and synchronous metastasis have been reported in approximately 5% of BC. Here we describe a 55-years-old female with a history of left-side BC and again diagnosed in 2019 with right-side BC tested ER-, PR-, ERBB2+ in breast tissue and triple negative in right axillary lymph node. The right BC and lymph node metastasis samples were tested by chromosomal microarray (CMA); the BC sample harbored more DNA copy number alterations than the lymph node specimen, suggesting that the lymph node metastasis was not directly originating from a dominant tumor clone in the right BC. This case highlights discordant ERBB2 status that can benefit from assessment of ERBB2 in both primary and metastatic specimens. This case also demonstrates the value of using CMA to help understand the clonal evolution of breast cancer metastasis especially when there are discordant biomarker results between primary and metastatic lesions.</p>","PeriodicalId":72513,"journal":{"name":"Cancer medicine journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328523/pdf/nihms-1594909.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38108532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of Oncology and Transplant Literature for the Management of Hepatic and Pancreatic Resections in Jehovah's Witnesses.","authors":"Hassan Aziz,&nbsp;Yuri Genyk,&nbsp;Muhammad Wasif Saif,&nbsp;Alexandra Filkins,&nbsp;Rick Selby,&nbsp;Mohd Raashid Sheikh","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Jehovah's Witnesses undergoing liver or pancreas surgery represent a unique medical and ethical challenge. For hepatic and pancreatic malignancies, resections are currently the only curative treatment. These surgeries pose a risk for significant blood loss, for which blood transfusions are traditionally given. However, blood transfusions are considered unacceptable to many Jehovah's Witnesses patients. As the technology of surgery as well as development of new products continue to evolve, transfusion-less surgery modalities have been utilized for Jehovah's Witnesses. The use of these transfusion-less techniques is not yet standardized for hepatic and pancreatic resections. We aimed to review both oncology and transplant medical literature on pancreatic and hepatic resection to develop guidelines for the management Jehovah's Witnesses patients.</p>","PeriodicalId":72513,"journal":{"name":"Cancer medicine journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324029/pdf/nihms-1601027.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38104361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Same-Day Administration of Pegfilgrastim in Patients Receiving Chemotherapy for Gastrointestinal Malignancies.","authors":"Robert M Matera,&nbsp;Valerie Relias,&nbsp;Muhammad Wasif Saif","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Pegfilgrastim is typically administered 24 hours after chemotherapy per package insert; however some patients are unable or unwilling to return for this additional visit due to work or transportation especially with regimens consisting of infusional 5-FU. Same-day dosing eliminates need for this additional visit. Results from prior studies in other tumor types are inconclusive as few support same-day dosing whereas others show inferiority. Purpose of our study was to determine safety and efficacy of administering pegfilgrastim on same day as chemotherapy in patients with gastrointestinal (GI) malignancies.</p><p><strong>Method: </strong>A single-institution retrospective review was conducted of 69 patients with GI malignancies who received chemotherapy and same-day pegfilgrastim (6 mg) within 1 hour of completion of chemotherapy from Jan 2014 through Jan 2017. As per institutional guidelines, patients were counseled on risks of same-day pegfilgrastim prior to its administration. These patients were compared with a set of 70 patients who received pegfilgrastim 24-hours after completing the chemotherapy for GI cancers.</p><p><strong>Result: </strong>A total of 536 chemotherapy cycles in 69 patients were analyzed. Median absolute neutrophil count nadir for all cycles was 4538/uL (Range: 1160 - 25168). Grade 1 and 2 neutropenia developed in 6 of 536 (1%) cycles. Bone pain reported in 3 patients (4%). There were no episodes of grade 3 or 4 neutropenia or febrile neutropenia. None had dose reductions, chemotherapy delays, hospitalizations, or antibiotic use due to neutropenia.</p><p><strong>Conclusion: </strong>We believe our study is the first in GI malignancies to report that same-day pegfilgrastim administration may be as effective and safe as next-day administration, benefiting patients and might reduce costs.</p>","PeriodicalId":72513,"journal":{"name":"Cancer medicine journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350279/pdf/nihms-1597375.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38152587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consequences of the COVID-19 Pandemic on Cancer Clinical Trials.","authors":"Sally Flores,&nbsp;Nita Kurian,&nbsp;Anu Yohannan,&nbsp;Christina Persaud,&nbsp;Muhammad Wasif Saif","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The battle against cancer is formidable even in normal circumstances and the COVID-19 selectively cancer patients with an increased risk of mortality by three times higher than those without cancer but also forced us to shut down the clinical trials in cancer patients to deal with the present crisis. We discuss here the disruptions on research in cancer with its immediate and delayed consequences and offer some suggestions to modify our practices, strategies and rationalization to help succeed the cancer treatment and research after the crisis is over.</p>","PeriodicalId":72513,"journal":{"name":"Cancer medicine journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324032/pdf/nihms-1599402.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38104362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is there an Ethnic Predisposition to Developing Brain Metastases (BM) in Asian Patients with Colorectal Cancer?","authors":"Kerri McGovern,&nbsp;Melissa H Smith,&nbsp;Antonia Maloney,&nbsp;Jyothi Jose,&nbsp;Muhammad Wasif Saif","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Most common sites of metastases in patients with colorectal cancer (CRC) include liver and lung. Brain metastases are very rare but their presence is associated with a poor prognosis and shorter survival. We report our investigation into the impact of race/ethnicity on the incidence of BM in CRC patients.</p><p><strong>Method: </strong>We retrospectively reviewed patients diagnosed with CRC from 2010 - 2018 at a single institution and analyzed any association of development of brain metastases with race and ethnicity. Race and ethnicity were defined in accordance with federal standards set by the US Census.</p><p><strong>Result: </strong>We identified 264 CRC patients and 76(29%) were identified as Asian. Of those 76 patients, 5(7%) developed brain metastases. All 5 patients were male and stage IV at initial diagnosis. Brain metastases was a late stage phenomenon. Median time to development of brain metastases was 29 months (Range: 26 - 33). Median overall survival after BM diagnosis was 5.5 months (Range: 4 - 11). Overall survival was longest for the patient who had both radiation and surgery.</p><p><strong>Conclusion: </strong>Our study showed an incidence of brain metastases of 7% in the Asian sub-population compared to the historical control of 0.6% - 3.2% in the overall population. These results at the least warrant further investigation in a larger patient population of brain metastases in CRC patients with emphasis on molecular markers.</p>","PeriodicalId":72513,"journal":{"name":"Cancer medicine journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311021/pdf/nihms-1597381.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38082781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Potential Options for SBRT in Pancreatic Cancer.","authors":"Maged Ghaly,&nbsp;Emile Gogineni,&nbsp;Joseph Herman,&nbsp;Muhammad W Saif","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Stereotactic body radiotherapy (SBRT) is an emerging treatment option for patients with pancreatic cancer, as it can provide a therapeutic benefit with significant advantages for patients' quality of life over standard conventional chemoradiation (CRT). The objective of this review is to present alternative clinical settings in which SBRT may benefit patients with pancreatic cancer. These include palliation of pain, elderly patients who are not surgical candidates, local therapy in oligometastatic cases and salvaging local failures after surgery or external beam radiation. We will review these individually and provide supporting literature for each.</p>","PeriodicalId":72513,"journal":{"name":"Cancer medicine journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336074/pdf/nihms-1685657.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39280748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First Analysis of Same-day Pegfilgrastim Use with Concurrent Capecitabine-based Regimens in Patients with Gastrointestinal Malignancies.","authors":"Muhammad Wasif Saif,&nbsp;Nausheen Hakim,&nbsp;Jeffrey Chi,&nbsp;Hasan Rehman,&nbsp;Shreya Prasad Goyal,&nbsp;Coral Olazagasti,&nbsp;Patnita Forde Sheperd,&nbsp;Jyothi Jose","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Pegfilgrastim is administered 24 hours. after chemotherapy to reduce risks of myelosuppression. This requires an additional clinic visit, which can be difficult for some patients (pts) due to work and transportation issues. In GI malignancies, patients receiving capecitabine-based regimens also require pegfilgrastim to reduce myelotoxicity. We present here the first study to analyze safety and efficacy of administering pegfilgrastim on the same day as capecitabine-based regimens in patients with GI malignancies.</p><p><strong>Methods: </strong>We evaluated 157 patients with GI malignancies who received a capecitabine-based chemotherapy regimen, including XELOX, EOX, ECX, XELIRI, MIXE, gemcitabine-capecitabine and same-day pegfilgrastim (6 mg) within 1 hr of completion of systemic agents. As per institutional guidelines, patients were counseled on risks of same-day pegfilgrastim prior to its administration. Patients were followed to determine the degree of neutropenia and toxicity.</p><p><strong>Results: </strong>A total of 914 chemotherapy cycles in 157 patients were analyzed. Median ANC nadir for all cycles was 5634/uL (range: 450 - 23800). Grade 1 and 2 neutropenia developed in 11 of 914 cycles. Bone pain reported in 9 pts. There was 1 episode of grade >3 neutropenia resulting in infection and antibiotic use. No other patient required dose reductions, chemotherapy delays, or hospitalizations. No increased toxicity of capecitabine was noticed.</p><p><strong>Conclusions: </strong>We believe our study is the first in GI malignancies to report that same-day pegfilgrastim administration with capecitabine-based regimens may be as effective and safe as next-day administration. Additionally, given the absence of CD in human bone marrow, it appears capecitabine can be used concurrently with pegfilgrastim. Prospective studies should be done to further investigate, as this practice can benefit patients clinically, decrease office visits, increase patient's satisfaction and reduce healthcare costs.</p>","PeriodicalId":72513,"journal":{"name":"Cancer medicine journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903891/pdf/nihms-1662938.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25424616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Spiritual Therapeutic Assessment in Terminal Ill Diagnosis: Focus on Meaning and Spirituality","authors":"Demkhosei Vaiphei Suantak","doi":"10.46619/CMJ.2020.3-1022","DOIUrl":"https://doi.org/10.46619/CMJ.2020.3-1022","url":null,"abstract":"There is no doubt that the modern scientific medicine helps in sustaining human life, but tends to forget terminal ill experiences unlike other illness is accompanied by several mental and psychological factors. The core criteria to deliver quality of life in terminal illness are to assess its bi-products like mental disharmony, depression, and the psychological issues. The spiritual psychotherapy is a modern humanistic approach that has holistic view on human illness in health and medical sciences. It is an effective coping mechanism to cope with stress, anxiety, depression, and suffering that are frequently experienced by terminally ill patients to delivered quality of life and meaning making policy in the clinical settings. Palliative end-of-life care on the other hand main objective is to improve quality of life of the terminal patients and the family that includes the physical, psychological, and spiritual wellbeing assessments. Considering the helplessness conditions of the terminal patients the spiritual psychotherapy is the urgent needs as it viewed human illness as the complex interplay between the biopsychosocial-spiritual factors. Especially when the patient is in the context of healing impossibility, spirituality plays an important role in meeting the needs of the dying individual’s before the inevitable death strikes. Objective/Purpose The purpose of this analytical review is to ponder on the role of spirituality in meaning-making and a source of hope mainly when cure is not possible in the terminal experiences. It is also to find out how spirituality serves as a coping mechanism in the face of inevitable death and makes life more meaningful to the dying individuals. Method The propose study will use philosophical inquiry on the existing literatures.","PeriodicalId":72513,"journal":{"name":"Cancer medicine journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91175800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effective Ways of Breaking Bad News in Terminal Ill Diagnosis: Focus on Strategies","authors":"Demkhosei Vaiphei Suantak","doi":"10.46619/CMJ.2020.3-1021","DOIUrl":"https://doi.org/10.46619/CMJ.2020.3-1021","url":null,"abstract":"In terminal diagnosis breaking bad news is one of the most difficult tasks for every clinicians working in the palliative endof-life care, but a must in its clinical practices. It requires special skills and the ability to deliver the bad news without hurting the sentiment of the patient and the loved ones. Many clinicians working in the palliative care are incompetent in handling the process of delivering the bad news, mainly due to the lack of effective communication skills and sometime were preoccupied with fear and nervousness. A time of breaking bad news is consider to the most crucial moment where the dying individuals are mostly accompanied with several negative feelings and emotional breakdown, which require a well structure manner and well design techniques to put forward. Yet little of its skills and techniques are known among the medical practitioners as a whole in their medical curriculum during their training period. Delivering bad news requires clinicians advance preparations on how much information the patient and the family would like to acquire, quality therapeutic relationship, and emotionally well prepared. The challenges lies in breaking bad news an important domain in terminal diagnosis, but the clinicians are mostly not aware on how, when, and where to deliver in its clinical practices that usually creates a communication gap between the clinicians and the patient.","PeriodicalId":72513,"journal":{"name":"Cancer medicine journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78229013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapy of Bladder Cancer","authors":"Khamar Bakulesh","doi":"10.46619/CMJ.2020.3-1020","DOIUrl":"https://doi.org/10.46619/CMJ.2020.3-1020","url":null,"abstract":"Bladder cancer used to be the only cancer treated by immunotherapy in form of intravesical BCG. Since approval of BCG for Non muscle invasive bladder cancer (NMIBC), there has been significant advancement in our knowledge about immune alteration in cancer and availability of immunotherapeutic agents. Tumor induced cell mediated immunosuppression is identified as a key factor for development and progression of cancer. Immune suppression in bladder cancer is predominantly through Macrophages. Myeloid derived suppressor cell, NK cells, Treg and expression of immune checkpoint receptor inhibitors also contribute to immune suppression. BCG induces innate immune response and its efficacy is limited to NMIBC. Novel immunotherapeutic agents evaluated in bladder cancer are administered locally or systemically to induce innate or adaptive immune response. Systemic administration of antibodies against PD-1/PD-L1 axis are now approved for treatment of locally advanced/metastatic bladder cancer as a first line as well as second line therapy. Pembrolizumab is also approved for BCG unresponsive NMIBC. Since response to immunotherapy are neither uniform nor universal, attempts are made to identify prognostic and predictive biomarkers. Identified biomarkers lack desired specificity and sensitivity. Several immune approaches using innate as well as adaptive mechanism are under evaluation to improve outcome of intravesical BCG or immune check point receptor inhibitors.","PeriodicalId":72513,"journal":{"name":"Cancer medicine journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79840743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}